Form 4: Stoke Therapeutics GC Acquires Shares, Receives New PSUs

Stoke Therapeutics' General Counsel, Jonathan Allan, acquired 6,000 common shares and received a new grant of 12,000 performance stock units.

Summary

• Jonathan Allan, General Counsel & Corporate Secretary of Stoke Therapeutics, Inc. (STOK), acquired 6,000 shares of common stock on August 14, 2025, through the exercise of derivative securities at a price of $0.
• Following this transaction, Allan beneficially owns 25,631 shares of common stock.
• Allan also received a new grant of 12,000 Performance Stock Units (PSUs) on August 14, 2025, at a price of $0.
• Each PSU represents a right to receive one share of the Issuer's common stock, contingent on the achievement of certain performance criteria as certified by the Issuer's compensation committee.
• Half of the newly granted PSUs will vest on August 14, 2025, and the remaining half will vest on August 14, 2026, subject to Allan's continued service to the Issuer.
• After these transactions, Allan beneficially owns 12,000 derivative Performance Stock Units.

Sentiment

Score: 7

Explanation: The filing indicates a routine executive compensation event, including the acquisition of shares and a new grant of performance units, which generally signals continued executive commitment and aligns interests with shareholders. There are no negative disclosures.

Positives

• Jonathan Allan, a key executive, increased his direct ownership of common stock by 6,000 shares, demonstrating continued alignment with shareholder interests.
• The grant of 12,000 new Performance Stock Units (PSUs) indicates ongoing compensation and incentives tied to company performance and continued service.
• The vesting schedule for the PSUs extends through August 2026, suggesting a commitment from the General Counsel to the company's long-term success.

Risks

• The vesting of the newly granted Performance Stock Units is subject to Jonathan Allan's continued service to Stoke Therapeutics, Inc. on the relevant vesting dates.
• The award of Performance Stock Units is contingent upon the achievement of certain performance criteria, which may not be met.

Future Outlook

The future outlook for Jonathan Allan's equity compensation includes the vesting of 6,000 Performance Stock Units on August 14, 2025, and an additional 6,000 Performance Stock Units on August 14, 2026, contingent on his continued service and the achievement of performance criteria.

Industry Context

This Form 4 filing reflects a routine executive compensation event within the biotechnology or pharmaceutical industry, where equity-based incentives like Performance Stock Units are common tools to align executive interests with long-term company performance and shareholder value.

Stakeholder Impact

• Shareholders: The acquisition of common stock and grant of performance units to a key executive like the General Counsel can be viewed positively as it aligns management's interests with shareholder value creation and demonstrates continued commitment to the company.

Next Steps

• Vesting of 6,000 Performance Stock Units on August 14, 2025.
• Vesting of the remaining 6,000 Performance Stock Units on August 14, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation transaction, specifically the exercise of equity awards and the grant of new performance stock units. While it shows continued insider ownership and alignment, it does not contain new material information about the company's financial performance, strategic direction, or operational results that would warrant a change in investment recommendation. It is a standard disclosure of an executive's equity movements.

Keywords

Stoke Therapeutics, STOK, Jonathan Allan, General Counsel, Corporate Secretary, SEC Form 4, Insider Trading, Stock Acquisition, Performance Stock Units, PSU, Equity Compensation, Executive Compensation, Common Stock, Beneficial Ownership